NeuroScienceLab Essen
Junior-Prof. Dr. rer. nat. Ana I. Casas

Group leader "Network pharmacology for neurovascular diseases"
Office: IG1, 9th floor, room 9.004
Phone: +49 201 723 82854
Fax: +49 201 723 79030

Ana I. Casas received her Bachelor's degree in Biotechnology in 2013 at the Pablo de Olavide University (Seville, Spain), followed by a Master's in Neuropsychopharmacology at the Autonomous University of Madrid (Spain) in 2014. She finished her doctoral thesis focused on Network pharmacology as a neuroprotective therapy in ischemic stroke in 2018 with the maximal academic distinction at the University of Maastricht (The Netherlands). Last 2020 she relocated to Germany after being awarded a senior postdoctoral DFG Fellowship at the Department of Neurology (University Hospital Essen). In 2022 she was appointed as Junior Professor at the University Duisburg-Essen and currently acts as group leader of the research group "Network pharmacology for neurovascular diseases".
Research interests

Ana I. Casas is focused on the identification of novel therapeutic targets using systems medicine and bioinformatics tools followed by preclinical validation in different neurovascular animal models. Additionally, she follows both network pharmacology and drug repurposing strategies to maximally potentiate clinical translation.
Key publications

De Meyer S, Langhauser F, Haupeltshofer S, Kleinschnitz C, Ana I Casas. Thromboinflammation in Brain Ischemia: Recent Updates and Future Perspectives. Stroke 2022 Apr 1.

Nogales C, Mamdouh ZM, List M, Markus List, Christina Kiel, Ana I. Casas, Harald H.H.W. Schmidt. Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends Pharmacol Sci 2022; 43: 136-150. 2021/12/14.

Ana I. Casas, Hermann A.M. Mucke, Cristian Nogales, Alexandra Petraina, Antonio Cuadrado, Ana I. Rojo, Pietro Ghezzi, Vincent Jaquet, Fiona Augsburger, Francois Dufrasne, Jalal Soubhye, Soni Deshwal, Moises Di Sante, Nina Kaludercic, Fabio Di Lisa, and Harald H.H.W. Schmidt. On the clinical pharmacology of reactive oxygen species. Pharmacological reviews, 2020 Oct;72(4):801-828

Esther Parada*, Ana I. Casas*, Alejandra Palomino-Antolin, Vanessa Gómez-Rangel, Alfonso Rubio-Navarro, Victor Farré-Alins, Paloma Narros-Fernández, Melanie Guerrero- Hue, Juan Moreno, Juliana Rosa, José Roda, Borja Hernández-García, Javier Egea. Early TLR4 blockade reduces ROS and inflammation triggered by microglial pro-inflammatory phenotype in rodents and human brain ischemia models. British Journal of Pharmacology (BJP), 2019 Jun;1-16 *Equally contributed to this work

Ana I. Casas, Ahmed A. Hassan, Simon J. Larsen, Vanessa Gomez-Rangel, Mahmoud Elbatreek, Pamela W. M. Kleikers, Emre Guney, Javier Egea, Manuela G. Lopez, Jan Baumbach, Harald H.H.W. Schmidt. From single drug targets to synergistic network pharmacology in ischemic stroke. Proc. Natl. Acad. Sci. (PNAS), 2019 Apr 2;116(14):7129- 7136

Ana I. Casas, Pamela W.M. Kleikers, Eva Geuss, Friederike Langhauser, Thure Adler, Dirk H. Busch, Valerie Gailus-Durner, Martin Hrabê de Angelis, Javier Egea, Manuela G. Lopez, Christoph Kleinschnitz , and Harald H.H.W. Schmidt. Calcium-dependent reactive oxygen formation and blood-brain barrier breakdown by NOX5 limits post-reperfusion benefit in stroke. Journal of Clinical Investigation (JCI), 2019 Mar 18;130:1772-1778

Friederike Langhauser*, Ana I. Casas*, Vu-Thao-Vi Dao, Emre Guney, Jörg Menche, Eva Geuss, Pamela W.M. Kleikers, Manuela G. López, Albert-L. Barabási, Christoph Kleinschnitz & Harald H.H.W. Schmidt. A diseasome cluster-based drug repurposing of soluble guanylate cyclase activators from smooth muscle relaxation to direct neuroprotection. npj (nature) | Systems Biology & Applications, 2018 Feb 5;4:8. vol.4 (1) pp. 8 *Equally contributed to this work

Ana I Casas*, Eva Geuss*, Pamela WM Kleikers, Stine Mencl, Alexander M. Herrmann, Izaskun Buendia, Javier Egea, Sven G. Meuth, Manuela G Lopez, Christoph Kleinschnitz, Harald HHW Schmidt. NOX4-dependent neuronal autotoxicity and blood-brain barrier breakdown explain the superior sensitivity of the brain to ischemic damage. Proc. Natl. Acad. Sci. (PNAS). 2017 vol.114 (46) pp. 12315- 12320. *Equally contributed to this work
NeuroScienceLab Sekretariat